<DOC>
	<DOC>NCT00859807</DOC>
	<brief_summary>The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).</brief_summary>
	<brief_title>A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight &gt;45 kg (99 lbs). An informed consent document signed and dated by the subject or a legally acceptable representative. A history of drug induced agranulocytosis and history of liver and hematological problems while taking amodiaquine. Any condition possibly affecting drug absorption (eg, gastrectomy). A positive urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Amodiaquine suspension</keyword>
	<keyword>Flavoquine tablets</keyword>
	<keyword>Bioequivalence study</keyword>
</DOC>